pneumococcal vaccine
Jump to navigation
Jump to search
Indications
- prevention of pneumonia due to Streptococcus pneumoniae
- adults >= 65 years of age[2]
- or >= 19 years of age with:
- immunocompromised condition (HIV, cancer, renal disease)*
- functional or anatomic asplenia*
- immunosuppression
- pneumococcal vaccination associated with lower risk for both mild & severe respiratory infections in patients taking long-term immunosuppressants[18]
- immuncompetent patients*
- CSF leaks, or cochlear implants*
- COPD, smoking, heart disease*
- diabetes mellitus, chronic liver disease, alcoholism*
- chronic renal failure[3]*
- hemoglobinopathy*
- immunocompromised condition (HIV, cancer, renal disease)*
- comparison of protection from different pneumococcal vaccines:[12]
vaccine | serotypes for which protection afforded |
---|---|
PCV13 | Block-1 |
PCV15 | Block-1 + Block-2 |
PCV20 | Block-1 + Block-2 + Block-3 |
PPSV23 | Block-1 + Block-2 + Block-3 + Block-4 (except 6A in Block-1) |
Block-1: serotypes: 1, 2, 3, 4, 5, 6A, 6B, 7F,14, 18C, 19A, 19F, 23F
Block-2: serotypes: 22F, 33F
Block-3: serotypes: 8, 10A, 11A, 12F, 15B
Block-4: serotypes: 2, 9N, 17F, 20
Contraindications
- does not reduce risk of dementia
- hypersensitivity to pneumococcal vaccine, diptheria toxoid or any component
Management
- Advisory Committee on Immunization Practices (ACIP) recommends routine use of:
- 15-valent pneumococcal conjugate vaccine (Prevnar)* + 23-valent pneumococcal polysaccharide vaccine (Pneumovax) in this order 1 year later (CDC)[7]
- 20-valent Prevnar (PCV20) without Pneumovax (PPSV23) 1 year later is alternative[7]
- FDA approves Capvaxive (Pneumococcal 21-valent Conjugate Vaccine)[17]
- PCV13 no longer recommended (except for nursing home residents)[9], & PCV15 & PCV20 have replaced need for PCV13
- PCV13 had been recommended for elderly with immunosupression & for elderly with a CSF leak or a cochlear implant[8]
Vaccination schedule for PCV13 recipients[10]
prior vaccination | vaccines needed |
---|---|
PCV13 + PPSV23 | PCV20 >= 5 years after previous dose |
PCV13 only & healthy | PPSV23 or PCV20 at age 65 |
PCV13 only & immunocompromised | PPSV23 or PCV20 & repeat at age 65 |
* at least 1 year between vaccines
- older adults who have not previously received either vaccine should be given one dose of Prevnar (PCV15) followed by one dose of Pneumovax (PPSV23) 1 year later (CDC)[7]
- adults who have previously received Pneumovax should be given one dose of Prevnar (PCV15) or PCV20 at least 1 year after the last Pneumovax dose
- if a patient received both PCV13 + PPSV23 before age 65, PCV20 should be adminisered 5 years later
- if patient received either (PCV13 or PSV15) or PPSV23 before age 65, but not both, PCV20 may be administered after 1 year
- PCV20 may be administered to patients who have received PCV13 at any age & PPSV23 at age >= 65 years (5 years after PPSV23)
- if a patient received a PPSV23 dose before age 65, a 2nd dose should be administered 5 years later if Prevnar is not administered
- do not give PCV13
- PCV13 is expensive & unnecessary for healthy elderly[5]
- PCV13 use was associated with reduced pneumonia hospitalization among Medicare beneficiaries >= 65 years[11]
- this would seem to implicate S pneumoniae serotype 6A (the only serotype not covered by PPSV23)
- in adults 65-74 years adjusted vaccine effectiveness (aVE) of PCV13 alone for preventing pneumococcal CAP is 66%, for PPSV23 alone, aVE is 18.5%, & for sequential PCV13/PPSV23 aVE is 80%[6];
- previous guidelines in 2021 recommended use of PPSV23 alone (2 doses) or PCV13 followed by PPSV23[16]
* PSV15 & PSV20 replace PSV13 in 2022[7]
* both PSV15 & PPSV23 recommended for immunocompromised patients & immunocompetent patients < 65 years of age who qualify[4][7]
* PSV20 recommended for immunocompetent patients < 65 years of age[4]
More general terms
More specific terms
- pneumococcal congugate vaccine (Prevnar, Prevnar 13, PCV13, Prevnar-20, PCV20, Prevnar-15, PCV15, Vaxneuvance, Capavaxive, PCV21, PHiD-CV10, PCV10, Synflorix)
- pneumococcal polysaccharide vaccine, polyvalent (PneumoVax 23, Pnu-Immune 23, PPSV-23)
References
- ↑ Centers for Disease Control & Prevention Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR October 12, 2012 / 61(40);816-819 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm
- ↑ 2.0 2.1 Tomczyk S et al Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >= 65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Weekly. September 19, 2014 / 63(37);822-825 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25233284 <Internet> http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a4.htm
- ↑ 3.0 3.1 Kobayashi M et al Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Weekly. September 4, 2015 / 64(34);944-947 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6434a4.htm
- ↑ 4.0 4.1 4.2 Medical Knowledge Self Assessment Program (MKSAP) 17, 18, 19. Board Basics. An Enhancement to MKSAP19. 2023 American College of Physicians, Philadelphia 2015, 2018, 20219.
- ↑ 5.0 5.1 Zuger A How Should We Use Conjugate Pneumococcal Vaccine in Immunocompetent Older Adults? NEJM Journal Watch. Jukt 25, 2019 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
- ↑ 6.0 6.1 Heo JY, Seo YB, Choi WS et al. Effectiveness of pneumococcal vaccination against hospitalized pneumococcal pneumonia in older adults: A prospective, test-negative study. J Infect Dis 2021 Sep 19; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/34537847 https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiab474/6372439
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 Melville NA CDC Issues New Pneumococcal Vaccine Recommendations for Adults. Medscape. Feb 1, 2022
Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:109-117 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35085226 Free article https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm
Centers for Disease Control and Prevention. Pneumococcal vaccination: Information for healthcare professionals. CDC 2022 Jan 24 https://www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html - ↑ 8.0 8.1 8.2 Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
- ↑ 9.0 9.1 Matanock A, Lee G, Gierke R, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >=65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:1069-1075 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31751323 PMCID: PMC6871896 Free PMC article
- ↑ 10.0 10.1 Sax PE Five Quick Questions from Our Course " ID in Primary Care" HIV and ID Observations. Nov 7, 2022 https://blogs.jwatch.org/hiv-id-observations/index.php/five-quick-questions-from-our-course-id-in-primary-care/2022/11/07/
- ↑ 11.0 11.1 Kobayashi M et al. Association of pneumococcal conjugate vaccine use with hospitalized pneumonia in Medicare beneficiaries 65 years or older with and without medical conditions, 2014 to 2017. JAMA Intern Med 2023 Jan; 183:40. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36469350 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2799225
- ↑ 12.0 12.1 From The Medical Letter on Drugs and Therapeutics. December 28, 2021 Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance JAMA. 2021;326(24):2521-2522. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34962532 https://jamanetwork.com/journals/jama/fullarticle/2787554
- ↑ 13.0 13.1 Douros A et al. Common vaccines and the risk of incident dementia: A population-based cohort study. J Infect Dis 2022 Dec 21; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36542511 https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiac484/6948438
Salmon DA et al. Commentary on "Common vaccines and the risk of dementia: a population-based cohort study": Science can be messy but eventually leads to truths. J Infect Dis 2022 Dec 21; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/36542509 https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiac487/6950650 - ↑ Prevnar20 https://prevnar20adult.pfizerpro.com/acip-recommendations
- ↑ Centers for Disease Control & Prevention Public Health Surveillance. September 29, 2023 2016-2021 Serotype Data for Invasive Pneumococcal Disease Cases by Age Group from Active Bacterial Core surveillance https://data.cdc.gov/Public-Health-Surveillance/2016-2021-Serotype-Data-for-Invasive-Pneumococcal-/qvzb-qs6p
- ↑ 16.0 16.1 Kobayashi M, Pilishvili T, Farrar JL et al. Pneumococcal vaccine for adults aged >= 19 years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 2023 Sep 8;72(3):1-39. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37669242 PMCID: PMC10495181 Free PMC article. https://www.cdc.gov/mmwr/volumes/72/rr/rr7203a1.htm
- ↑ 17.0 17.1 Ellis R FDA Approves New Pneumococcal Vaccine. Medscape. June 18, 2023 https://www.medscape.com/viewarticle/fda-approves-new-pneumococcal-vaccine-2024a1000bcm
- ↑ 18.0 18.1 Nakafero G et al. Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: A case-control study. Lancet Rheumatol 2024 Sep; 6:e615. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39067457 Free article https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(24)00128-0/fulltext